Author of

• 36479

  +

  P79 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy (ID 256)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Immunotherapy (Phase II/III Trials)
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 36487

    +

    P79.07 - Comparative Efficacy and Safety of PD-(L)1 Inhibitors Combined with 1st-Line Chemotherapy for Advanced NSCLC: A Meta-Analysis (ID 3072)

    00:00 - 00:00  |  Presenting Author(s): Alessandro Di Federico
    • Abstract
    • Slides

    Introduction
    

    The addition of PD-(L)1 inhibitors to first-line chemotherapy (CT) demonstrated to improve the outcomes of advanced non-small cell lung cancer (NSCLC) patients. Nonetheless, no direct comparison exists between these agents.

    Methods
    

    We performed a meta-analysis of available randomized controlled clinical trials (RCT) to assess and compare the efficacy and safety of PD-(L)1 inhibitors in combination with first-line CT for advanced NSCLC patients, independently from PD-L1 expression.

    Results
    

    7 RCT (4 testing atezolizumab and 3 testing pembrolizumab) were included in the analysis. Overall, the addition of a PD-(L)1 inhibitor to CT improved both Progression-Free Survival (PFS) [HR: 0.60; 95% CI, 0.56-0.65] and Overall Survival (OS) [HR: 0.75; 95% CI, 0.69-0.82]. When compared, PFS was better with pembrolizumab [HR: 0.52; 95% CI, 0.46-0.59] than atezolizumab [HR: 0.64; 95% CI 0.59-0.71], and so was OS [(HR for pembrolizumab: 0.63; 95% CI, 0.54-0.73) versus (HR for atezolizumab: 0.82; 95% CI, 0.74-0.91)]. The risk of grade >=3 treatment-related adverse events was significantly increased with the addition of atezolizumab to CT [RR: 1.23; 95% CI 1.15-1.31], but not with the addition of pembrolizumab to CT [RR: 1.03; 95% CI 0.95-1.12].

    

    

    Conclusion
    

    Based on this meta-analysis of published data, the addition of pembrolizumab to first-line CT showed statistically significant better outcomes and less toxicity when compared to atezolizumab in advanced NSCLC, independently from PD-L1 status.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.